Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies

Rheumatology (United Kingdom)

Volumn 56, Issue 2, 2017, Pages 287-293

  Liang, Wen Chen ^a,b   Uruha, Akinori ^c   Suzuki, Shigeaki ^c   Murakami, Nobuyuki ^d   Takeshita, Eri ^d,e   Chen, Wan Zi ^a   Jong, Yuh Jyh ^f,g,h   Endo, Yukari ^c,e   Komaki, Hirofumi ^e   Fujii, Tatsuya ⁱ   Kawano, Yutaka ^j   Mori Yoshimura, Madoka ^e   Oya, Yasushi ^e   Xi, Jianying ^k   Zhu, Wenhua ^c,k   Zhao, Chongbo ^k,l   Watanabe, Yurika ^c   Ikemoto, Keisuke ^c,m   Nishikawa, Atsuko ^c,n   Hamanaka, Kohei ^c   Mitsuhashi, Satomi ^c   Suzuki, Norihiro ^c   Nishino, Ichizo ^c   more..

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^h NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

ⁱ Shiga Medical Center for Children   (Japan)

^j SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^k FUDAN UNIVERSITY   (China)

^l Department of Neurology   (China)

^m Sales Department   (Japan)

ⁿ UNIVERSITY OF YAMANASHI   (Japan)

more..

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase (HMGCR); Immune mediated necrotizing myopathy; Major histocompatibility complex (MHC); Membrane attack complex (MAC); Muscular dystrophy; Paediatrics

Indexed keywords

ALPHA DYSTROGLYCAN; ALPHA SARCOGLYCAN; ANTIBODY; BETA DYSTROGLYCAN; CALPAIN 3; CAVEOLIN 3; COLLAGEN TYPE 6; CORTICOSTEROID; CYCLOSPORIN A; DELTA SARCOGLYCAN; DYSFERLIN; DYSTROPHIN; EMERIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LAMININ ALPHA2; METHOTREXATE; MYCOPHENOLIC ACID; SIGNAL RECOGNITION PARTICLE; TACROLIMUS; UNCLASSIFIED DRUG; AUTOANTIBODY; HMGCR PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INFANT; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOPATHY; NEXT GENERATION SEQUENCING; ONSET AGE; PEDIATRIC NECROTIZING MYOPATHY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; IMMUNOLOGY; METABOLISM; MYOSITIS; PATHOLOGY; PRESCHOOL CHILD; SKELETAL MUSCLE;

ADOLESCENT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INFANT; MALE; MUSCLE, SKELETAL; MYOSITIS;

EID: 85014154652     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew386     Document Type: Article

References (25)

1. De Bleecker JL, De Paepe B, Aronica E et al. 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord 2015;25:268-72.
2. Luo YB, Mastaglia FL. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 2015;1852:622-32.
3. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420-8.
4. Christopher-Stine L, Casciola-Rosen LA, Hong G et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010;62:2757-66.
5. Mammen AL, Chung T, Christopher-Stine L et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713-21.
6. Allenbach Y, Drouot L, Rigolet A et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine 2014;93:150-7.
7. Ge Y, Lu X, Peng Q, Shu X, Wang G. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme a reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One 2015;10:e0141616.
8. Limaye V, Bundell C, Hollingsworth P et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 2015;52:196-203.
9. Ramanathan S, Langguth D, Hardy TA et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm 2015;2:e96.
10. Watanabe Y, Suzuki S, Nishimura H et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study (in Japan). Medicine 2015;94:e416.
11. Werner JL, Christopher-Stine L, Ghazarian SR et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012;64:4087-93.
12. Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2015;2:e124.
13. Suzuki S, Yonekawa T, Kuwana M et al. Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. J Neuroimmunol 2014;274:202-8.
14. Scharner J, Brown CA, Bower M et al. Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Hum Mutat 2011;32:152-67.
15. Komaki H, Hayashi YK, Tsuburaya R et al. Inflammatory changes in infantile-onset LMNA-associated myopathy. Neuromuscul Disord 2011;21:563-8.
16. Rodriguez Cruz PM, Luo YB, Miller J et al. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord 2014;24:1025-35.
17. Hoogendijk JE, Amato AA, Lecky BR et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-45.
18. Rider LG, Shah M, Mamyrova G et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 2013;92:223-43.
19. Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008;35:927-9.
20. Suzuki S, Nishikawa A, Kuwana M et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015;10:61.
21. Suzuki S, Satoh T, Sato S et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology 2008;47:1539-42.
22. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 2015;68:689-94.
23. Ceribelli A, Fredi M, Taraborelli M et al. Prevalance and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 2014;32:891-7.
24. Hoshino K, Muro Y, Sugiura K et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010;49:1726-33.
25. Watanabe Y, Uruha A, Suzuki S et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotizing myopathy. J Neurol Neurosurg Psychiatry 2016;87:1038-44.